Apoptosis, or programmed cell death, is an evolutionarily conserved mechanism essential for development and homeostasis in multicellular organisms. Dysregulation of the cell death process is associated with neurodegenerative diseases, autoimmunity and cancer. The second most common cancer of the hematologic system is multiple myeloma (MM), an incurable plasma cell malignancy. Plasma cells are professional secretory cells with a highly developed endoplasmic reticulum (ER) that is specialized for the production of thousands of antibody molecules per second. Bortezomib (Velcade(TM), PS-341), a specific inhibitor of the 26S proteasome, has shown significant anti-tumor activity against MM with a favorable toxicity profile and was recently approv...
The proteasome inhibitor bortezomib has been successfully used in cancer therapy. Proteasome inhibit...
The proteasome inhibitor bortezomib has been successfully used in cancer therapy. Proteasome inhibit...
Proteasome inhibitors (PI) are effective against multiple myeloma (MM), but the mechanisms of action...
OBJECTIVE: To determine whether the Unfolded Protein Response (UPR) sensors (PERK, ATF6 and IRE-1) c...
Multiple myeloma is characterized by the malignant proliferating antibody-producing plasma cells in ...
Multiple myeloma is characterized by the malignant proliferating antibody-producing plasma cells in ...
The presence of correctly folded nascent immunoglobulin within the endoplasmic reticulum (ER) provid...
To determine whether the Unfolded Protein Response (UPR) sensors (PERK, ATF6 and IRE-1) can be targe...
To determine whether the Unfolded Protein Response (UPR) sensors (PERK, ATF6 and IRE-1) can be targe...
Bortezomib (VELCADE™, formerly known as PS-341) is a selective and potent inhibitor of the proteasom...
Bortezomib (VELCADE™, formerly known as PS-341) is a selective and potent inhibitor of the proteasom...
<div><p>Inhibition of the proteasome is a widely used strategy for treating multiple myeloma that ta...
Over the past decade, the promising results of UPSIs (UPS inhibitors) in eliciting apoptosis in vari...
Inhibition of the proteasome is a widely used strategy for treating multiple myeloma that takes adva...
Plasma cells are the terminally differentiated effector cells of the humoral immune system. The majo...
The proteasome inhibitor bortezomib has been successfully used in cancer therapy. Proteasome inhibit...
The proteasome inhibitor bortezomib has been successfully used in cancer therapy. Proteasome inhibit...
Proteasome inhibitors (PI) are effective against multiple myeloma (MM), but the mechanisms of action...
OBJECTIVE: To determine whether the Unfolded Protein Response (UPR) sensors (PERK, ATF6 and IRE-1) c...
Multiple myeloma is characterized by the malignant proliferating antibody-producing plasma cells in ...
Multiple myeloma is characterized by the malignant proliferating antibody-producing plasma cells in ...
The presence of correctly folded nascent immunoglobulin within the endoplasmic reticulum (ER) provid...
To determine whether the Unfolded Protein Response (UPR) sensors (PERK, ATF6 and IRE-1) can be targe...
To determine whether the Unfolded Protein Response (UPR) sensors (PERK, ATF6 and IRE-1) can be targe...
Bortezomib (VELCADE™, formerly known as PS-341) is a selective and potent inhibitor of the proteasom...
Bortezomib (VELCADE™, formerly known as PS-341) is a selective and potent inhibitor of the proteasom...
<div><p>Inhibition of the proteasome is a widely used strategy for treating multiple myeloma that ta...
Over the past decade, the promising results of UPSIs (UPS inhibitors) in eliciting apoptosis in vari...
Inhibition of the proteasome is a widely used strategy for treating multiple myeloma that takes adva...
Plasma cells are the terminally differentiated effector cells of the humoral immune system. The majo...
The proteasome inhibitor bortezomib has been successfully used in cancer therapy. Proteasome inhibit...
The proteasome inhibitor bortezomib has been successfully used in cancer therapy. Proteasome inhibit...
Proteasome inhibitors (PI) are effective against multiple myeloma (MM), but the mechanisms of action...